Clinical Trial Update: Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating a sequential regimen of bendamustine debulking followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Ofatumumab (ofatumumab)
• bendammustine (bendamustine)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED